In vitro susceptibilities of Chlamydia pneumoniae (Chlamydia sp. strain TWAR)
- 1 September 1989
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 33 (9) , 1634-1635
- https://doi.org/10.1128/aac.33.9.1634
Abstract
The in vitro susceptibilities of two clinical isolates of Chlamydia pneumoniae from Brooklyn, N.Y., were determined for tetracycline, erythromycin, sulfamethoxazole, ciprofloxacin, and three new macrolides--azithromycin, clarithromycin, and roxithromycin. Clarithromycin was the most active drug tested, followed by the other macrolides, tetracycline, and ciprofloxacin.This publication has 5 references indexed in Scilit:
- In vitro susceptibilities of mycoplasmas and ureaplasmas to new macrolides and aryl-fluoroquinolonesAntimicrobial Agents and Chemotherapy, 1988
- In vitro drug susceptibility of Chlamydia sp. strain TWARAntimicrobial Agents and Chemotherapy, 1988
- Pneumonia Associated with the TWAR Strain of ChlamydiaAnnals of Internal Medicine, 1987
- A NewChlamydia psittaciStrain, TWAR, Isolated in Acute Respiratory Tract InfectionsNew England Journal of Medicine, 1986
- An Epidemic of Mild Pneumonia Due to an Unusual Strain of Chlamydia psittaciThe Journal of Infectious Diseases, 1985